# A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

> **NCT02392624** · PHASE4 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 206 (actual)

## Conditions studied

- Urticaria

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02392624
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-18
- **Primary completion:** 2017-03-09
- **Final completion:** 2017-03-09
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02392624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02392624, "A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02392624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*